Present detailed Phase 2 clinical development program
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 4 Nov 2021
- Due
- 31 Mar 2022
- Delivered
- March 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Detailed Phase 2 clinical development program including patients with liver metastases to be presented in Q1 2022”
What we found
Evidence strength A What the grades mean
The company confirmed in a May 2022 filing that it presented its detailed strategy and clinical development plan for RP2/3 at a virtual investor event in March 2022.
-
A Replimune Group, Inc. 8-K filed 2022-05-19
“Provided detailed strategy and clinical development plan for RP2/3 at a virtual investor event in March 2022.” ✓ confirmed on the page
Market reaction: the shares moved -1.4% against the S&P 500 over the three sessions around the disclosure (18 May 2022 to 23 May 2022). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Present
- Deliverable
- Detailed Phase 2 clinical development program
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-REPL-002637 · Corrections policy